



## Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018

October 23, 2018

BOULDER, Colo., Oct. 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, October 30, 2018. Ron Squarer, Chief Executive Officer, will lead the call.

**Date:** Tuesday, October 30, 2018  
**Time:** 9:00 a.m. Eastern Time  
**Toll-Free:** (844) 464-3927  
**Toll:** (765) 507-2598  
**Pass Code:** 5559328

### Webcast, including Replay and Conference Call Slides:

<https://edge.media-server.com/m6/p/kdv5h8qp>

### About Array BioPharma

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI<sup>®</sup> (encorafenib) capsules in combination with MEKTOVI<sup>®</sup> (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a *BRAF*<sup>V600E</sup> or *BRAF*<sup>V600K</sup> mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in *BRAF*-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), larotrectinib and LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Ganovo<sup>®</sup> (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit [www.arraybiopharma.com](http://www.arraybiopharma.com) or follow @arraybiopharma on Twitter and LinkedIn.

### CONTACT:

#### Array BioPharma

Andrea N. Flynn, Ph.D.  
Senior Director, Investor Relations & Corporate Communications  
(303) 381-6600  
[ir@arraybiopharma.com](mailto:ir@arraybiopharma.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2019-on-october-30-2018-300735608.html>

SOURCE Array BioPharma